Home›Trial›NCT06262399
NCT06262399ENROLLING BY INVITATION

Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002

Study Summary

This is a follow-up study of subjects who received NTLA-2002 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.

Conditions
Hereditary Angioedema
Interventions / Drugs
View on ClinicalTrials.gov ↗
Sponsor
NTLA
Intellia Therapeutics
Gene Editing
C55/100
Study Details
Enrollment100 participants
Primary Completion—
Lead SponsorIntellia Therapeutics
Data Retrieved2026-04-11 04:23:01.073833+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Current status: ENROLLING BY INVITATION.

Enrolled: 100 participants
Sponsor Catalyst Profile

Intellia Therapeutics (NTLA) is the sponsoring company for this trial. BiotechSign currently grades this company C (55/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

NTLA Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.